Search the Newsreel

SeaStar Medical Q2 Results: Revenue up 82% YoY to $0.6 million

SeaStar Medical (NASDAQ: ICU) reported an 82% year-over-year revenue increase to $0.6 million in Q2 2026, driven by demand for its pediatric AKI therapy, QUELIMMUNE. Despite this growth, the company's net loss widened to $3.7 million due to increased R&D spending on its adult …

Seastar medical targets NEUTRALIZE-AKI enrollment completion around year-end or Q1 2027 as QUELIMMUNE adoption reaches 20 hospitals

Earnings Call Insights: SeaStar Medical Holding Corporation (ICU) Q2 2026 MANAGEMENT VIEW * "We are very pleased with our progress this quarter" and "Our pediatric AKI market penetration and continued strong QUELIMMUNE revenue growth bodes well for our future potential opportunity in the adult …

FDA Authorizes Medicus Pharma’s SkinJect Study for Gorlin Syndrome

Earnings call transcript: SeaStar Medical misses Q2 2026 forecasts as stock falls

SeaStar Medical reported a wider-than-expected loss and lower revenue for Q2 2026, leading to a stock decline despite an 82% increase in QUELIMMUNE therapy sales year-over-year. The company's NEUTRALIZE-AKI adult trial enrollment is progressing, with completion expected by year-end 2026 or early 2027, and …

Medicus Pharma (MDCX) widens loss as it raises $32M and adds secured notes

SeaStar Medical (ICU) grows QUELIMMUNE sales but warns on going concern

SeaStar Medical (ICU) reported increased net revenue from its FDA-approved pediatric QUELIMMUNE therapy for acute kidney injury, reaching $615,000 in Q2 2026 and $1.11 million year-to-date. Despite this growth, the company remains deeply loss-making with a net loss of $3.7 million for the quarter …

SEASTAR MEDICAL HOLDING ($ICU) Releases Q2 2026 Earnings

ICU Medical (ICUI) CIO Ben Sousa sells 2,250 shares of common stock

ICU Medical Inc./DE's Chief Information Officer, Ben Sousa, reported the sale of 2,250 shares of common stock on August 12, 2026, at a price of $178.3152 per share. This transaction leaves him with 3,076 shares of directly held common stock. The sale was executed …

ICU Medical (ICUI) insider plans to sell 2,250 shares of common stock

An insider at ICU Medical, Inc. (ICUI) plans to sell 2,250 shares of common stock with an aggregate market value of $401,209.20 through Morgan Stanley Smith Barney LLC Executive Financial Services. These shares were acquired via equity compensation events, including restricted stock vesting in …

Icu Medical Insider Sold Shares Worth $401,209, According to a Recent SEC Filing

An insider at ICU Medical (ICUI) sold shares valued at $401,209, as disclosed in a recent SEC filing. This transaction occurred on August 12, 2026, adding to previous insider sales announcements for the company. ICU Medical manufactures medical products for infusion therapy, vascular access, …

Farmer Mac Sets Payments for Three Common, Six Preferred Classes

Farmer Mac (NYSE: AGM) has announced its third-quarter 2026 dividends. This includes a $1.60 per share dividend for all three classes of its common stock, payable on September 30, 2026, to shareholders of record as of September 15, 2026. Additionally, the company declared quarterly …

SeaStar Medical Adds 3 Customers From Children's Hospitals for Its Therapy

Agriculture & Natural Solutions (ANSC) moves to remove shares and warrants from Nasdaq

Agriculture & Natural Solutions Acquisition Corp (ANSC) is delisting its Class A ordinary shares, warrants, and units from the Nasdaq Stock Market LLC. This action is a voluntary withdrawal by the issuer, compliant with both Nasdaq's rules and SEC regulations under Section 12(b) of …

Agriculture & Natural Solutions Acquisition Corporation(NasdaqGM:ANSC) dropped from NASDAQ Composite Index

Agriculture & Natural Solutions Acquisition Corporation (ANSC) has been removed from the NASDAQ Composite Index. This news follows previous reports on the company's earnings, including for the first quarter ended March 31, 2026, and its auditor raising 'Going Concern' doubt in March 2026 and …

Exicure Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against Exicure, Inc. (NASDAQ: XCUR) and reminds investors of the February 11, 2022 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Exicure made false and misleading …

ICU Medical Inc (ICUI) Insider Sell: Christian Voigtlander Disposes of 8,929 Shares

Christian Voigtlander, an insider at ICU Medical Inc (ICUI), recently sold 8,929 shares for approximately $1.63 million, reducing his direct ownership to 37,377 shares. This sale contributes to a trend of more insider selling than buying at ICUI over the past year (8 sells …

BERKLEY W R CORP Expands Stake in Agriculture & Natural Solutions Acquisition Corp (ANSC)

Cricut, Inc. Earnings Call Balances Growth and Strain

Icu medical director Elisha Finney sells $68,978 in stock

Elisha W. Finney, a director at ICU Medical Inc./DE (NASDAQ:ICUI), sold 378 shares of common stock for $68,978 on August 11, 2026. This transaction occurred as the stock neared its 52-week high, having returned 68% over the past year. Despite the sale, Finney still …

Icu medical COO Christian Voigtlander sells $1.63m in stock

ICU Medical COO Christian Voigtlander recently sold 8,929 shares of company stock for over $1.63 million, with transactions occurring on August 11, 2026, as the stock trades near its 52-week high. The company has shown strong financial performance, exceeding Q2 2026 expectations and raising …

Insider Selling: ICU Medical (NASDAQ:ICUI) COO Sells $1,633,381.97 in Stock

ICU Medical (NASDAQ:ICUI) COO Christian Voigtlander sold 8,929 shares of the company's stock for over $1.63 million, reducing his stake by 19.28%. This sale occurred after ICU Medical reported strong quarterly earnings, surpassing analyst expectations for both EPS and revenue, while maintaining its fiscal …

Goldman Sachs Group (ANSC) discloses 4.3% holding in Agriculture & Natural Solutions

ICU Medical (ICUI) COO sells 8,929 shares in open-market trade

ICU Medical Inc. (ICUI) Chief Operating Officer Christian B. Voigtlander sold 8,929 shares of common stock on August 11, 2026, at a weighted average price of $182.93 per share. This open-market transaction reduced his direct holdings to 37,377 shares. The sale amounted to approximately …

AtriCure (NASDAQ:ATRC) Sets New 12-Month High - Here's Why

AtriCure (NASDAQ:ATRC) reached a new 52-week high of $43.18, trading above its 50-day and 200-day moving averages. The company reported strong quarterly earnings, exceeding revenue estimates with $153.6 million and $0.18 EPS. Despite significant institutional ownership, insiders have sold shares totaling $1.78 million in …

ATRC: Strong growth, innovation, and clinical trial catalysts drive robust financial and market expansion

AtriCure, Inc. (ATRC) is experiencing strong growth and profitability, maintaining leadership in AFib and pain management. The company's financial performance is bolstered by innovation and operational leverage, with significant clinical trials expected to expand market opportunities. Free cash flow will be directed towards organic …

ICU Medical (ICUI) insider plans resale of 378 vested shares

An insider at ICU Medical Inc. (ICUI) plans to sell 378 shares of common stock, valued at $68,978.08, through Morgan Stanley Smith Barney LLC. These shares were acquired on May 13, 2020, as restricted stock vesting for services rendered. The filing indicates 25,007,000 shares …

ICU Medical (ICUI) files Form 144 for planned sale of 8,929 shares

ICU Medical, Inc. (ICUI) has filed a Form 144 indicating a planned resale of 8,929 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares, valued at approximately $1,633,403.62, are related to previously exercised options and vesting equity awards, …

ICUI Q2 Deep Dive: Margin Expansion and Infusion Systems Drive Outperformance

ICUI Q2 Deep Dive: Margin Expansion and Infusion Systems Drive Outperformance Medical device company ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results beating Wall Street's revenue expectations , but sales were flat year on year at $547.9 million. Its non-GAAP profit of $2.37 per share …

Australian Agricultural Company (ASX:AAC) Share Price in Focus for Investors

Agriculture & Natural Solutions Acquisition Corp Releases Q2 2024 10-Q Report

Agriculture & Natural Solutions Acquisition Corporation (ANSC) has released its Q2 2024 10-Q report, detailing financial performance including net income of $2.24 million for the quarter. The blank check company, formed to focus on decarbonizing agriculture and enhancing natural capital, completed its IPO in …

Australian Agricultural Company (ASX:AAC) Posts Record Operating Profit As Asset Gap Persists

How Icu Medical Inc. (ICUI) Affects Rotational Strategy Timing

This article analyzes Icu Medical Inc. (ICUI) through AI models, identifying strong sentiment across all horizons and no resistance levels above the current price, suggesting upside potential. It outlines three institutional trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk …

SeaStar Medical Holding Corp expected to post a loss of 97 cents a share - Earnings Preview

SeaStar Medical Holding Corp is expected to report an upcoming earnings loss. Analysts project the company will post a loss of 97 cents per share. This preview indicates anticipated financial performance ahead of their official earnings release.

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know What Happened? Shares of medical device company ICU Medical (NASDAQ:ICUI) jumped 10.2% in the afternoon session after the company posted strong second-quarter results that surpassed Wall Street expectations and raised its full-year earnings forecast. …

ICU Medical (ICUI) Following Raised 2026 Guidance Looks Modestly Undervalued

AtriCure (ATRC) Lifted Its Guidance, Is The Stock Fully Priced?

AtriCure (ATRC) has seen insider share sales despite reporting 13% Q2 revenue growth, returning to net income, and raising full-year guidance. While one valuation narrative suggests the stock is 11.9% undervalued at $47.00 due to potential market expansion from clinical trials, another analysis using …